doi: 10.1038/s41598-024-70707-w
Udvarhelyis read on the runway was that by 2025 competing in any line of business would require investments in claims platforms, AI-enabled utilization management, member engagement technology, and analytics infrastructure that no single-state plan could build in time
To view a copy of this license, visit About this article Cite this article Li, Y., He, Y., Cheng, W
When given at equimolar concentrations, tirzepatide shows greater weight loss but equal improvement in glucose metabolism relative to treatment with semaglutide in DIO mice (82)
By providing high-quality comparative data for non-CF cohorts, the CLEAR trial underscores the necessity of moving toward evidence-based, precision airway clearance therapies tailored specifically for the bronchiectasis population
Increasing GLP-1 naturally may help to support appetite and metabolic health, but its important to keep expectations realistic as the effects are usually modest compared to medications